Global clinical development of transcranial temporal interference stimulation: an analysis of registered human trials

医学 临床试验 干预(咨询) 随机对照试验 物理医学与康复 经颅直流电刺激 临床研究 试用登记 心理干预 磁刺激 梅德林 神经影像学 研究设计 脑刺激 脑深部刺激 临床研究设计 不利影响 物理疗法 电子数据采集
作者
Shihao Jiang,Rui Liu,Xuesong Bai,Zexing Li,Cong Fu,Tianyu Wang,Fuchao Yu,Linlin Ye,Lei Cao,Tao Wang,Yan Ma,Jiaqi Jin,张晓华,Liqun Jiao
出处
期刊:BMC Medicine [BioMed Central]
标识
DOI:10.1186/s12916-026-05363-0
摘要

Transcranial temporal interference stimulation (tTIS) is a noninvasive approach intended to engage deep or distributed brain targets. Despite a growing number of human studies, the global landscape, design characteristics, and reporting practices of registered tTIS trials remain unclear. We characterized the global clinical development of tTIS by examining registration trends, trial design, intervention reporting, and result availability. We searched nine international and regional clinical trial registries through April 30, 2026, to identify human interventional trials involving tTIS or related transcranial interferential stimulation approaches. Eligible records were deduplicated and coded for geography, indication, intended target, enrollment, design, stimulation parameters, device or platform information, safety reporting, and result availability. From 1,548 records, 168 unique trials were included. Registrations increased markedly after 2023 and were concentrated in China (79.8%) and the United States (11.3%). Psychiatric disorders were the leading indication group (39.8%), and target information was not reported in 75 trials (​4​4​.​6%). Among reported targets, subcortical structures predominated. Most trials involved a single center (94.6%), and 51.8% planned to enroll fewer than 50 participants. Randomization, masking, and sham control were reported in 69.6%, 74.4%, and 66.7% of trials, respectively. Among stimulation parameters, session duration was reported most frequently (40.5%). Device or platform information was reported in 12.5% of trials. At the data cutoff, 13 trials (7.7%) were classified as completed or terminated. Results were available for 8 trials (4.8%) from 10 sources. Registered tTIS research is expanding rapidly across diverse indications and intended targets, while clinical development remains at an early stage and intervention reporting remains incomplete. Greater transparency and consistency in trial registration and intervention documentation will enhance comparability across trials, facilitate protocol replication and evidence synthesis, and support the development of a more coherent evidence base for tTIS.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
乌龙茶发布了新的文献求助10
刚刚
为难完成签到,获得积分20
刚刚
Auster发布了新的文献求助10
刚刚
1秒前
科研通AI2S的应助被坦率采纳,获得10
1秒前
1秒前
教笑阳完成签到,获得积分10
1秒前
2秒前
2秒前
盖饭不加辣完成签到,获得积分10
3秒前
4秒前
4秒前
5秒前
starstar发布了新的文献求助10
5秒前
村村发布了新的文献求助10
5秒前
啾啾小船完成签到,获得积分10
6秒前
云墨发布了新的文献求助10
6秒前
李爱国的应助被Alice3088采纳,获得10
6秒前
7秒前
初初初啊发布了新的文献求助10
7秒前
future完成签到,获得积分10
7秒前
科研通AI6.2的应助被114514采纳,获得10
8秒前
koutianle发布了新的文献求助10
8秒前
8秒前
科研通AI6.4的应助被雪山大地采纳,获得10
9秒前
辣爆虾尾完成签到 ,获得积分10
10秒前
Jasper的应助被舍我其谁采纳,获得10
10秒前
10秒前
希望天下0贩的0的应助被loffm采纳,获得10
10秒前
10秒前
11秒前
12秒前
大意的麦片完成签到,获得积分20
12秒前
13秒前
覃浩洋发布了新的文献求助10
13秒前
瑾煊完成签到,获得积分20
13秒前
14秒前
loser完成签到,获得积分10
14秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8165074
求助须知:如何正确求助?哪些是违规求助? 9558738
关于积分的说明 21747291
捐赠科研通 7755624
什么是DOI,文献DOI怎么找? 3428780
关于科研通互助平台的介绍 2553162
邀请新用户注册赠送积分活动 2473361